The list is based on a rigorous evaluation process involving multiple rounds and criteria such as profitability in 2024, minimum revenue and market capitalization of 500 billion VND, and compound growth in revenue and profit. Forbes Vietnam also conducted qualitative research to assess the sustainable development of the companies, their industry positions, and profit sources.

DHG Pharma representative receives the "Top 50 Best Listed Companies in Vietnam 2025" award on 21/8. Photo: DHG Pharma

DHG Pharma representative receives the "Top 50 Best Listed Companies in Vietnam 2025" award on 21/8. Photo: DHG Pharma

Ranked 12th on the 2025 list, DHG Pharma (Hau Giang Pharmaceutical Joint Stock Company) is recognized for its strategic development, particularly its stable revenue and profit. The company falls within the mid-cap group and boasts strong financials, highly regarded by investors.

The long-standing company holds a leading market share in over-the-counter medications. Its multi-channel distribution network now reaches 30,000 traditional pharmacies (OTC), 3,546 stores within five major pharmacy chains (MTC), and 3,200 hospitals and clinics (ETC) nationwide. DHG Pharma also exports to 20 countries.

With two modern factories meeting JAPAN GMP and EU GMP standards, DHG Pharma serves as a role model for the pharmaceutical industry in raising production quality to international standards. Currently, only 10% of domestic factories meet similarly high standards. The company also benefits from the long-term involvement of its strategic shareholder, Taisho Pharmaceutical (Japan), which has helped standardize transparent governance and enhance international cooperation.

"Being recognized for 13 consecutive years affirms our position in the pharmaceutical industry and is a meaningful gift for the entire DHG Pharma team as we continue our journey of over half a century serving community health," said Toshiyuki Ishii, CEO of DHG Pharma, adding that the company is preparing to celebrate its 51st anniversary.

DHG Pharma owns two modern factories meeting JAPAN GMP and EU GMP standards. Photo: DHG Pharma

DHG Pharma owns two modern factories meeting JAPAN GMP and EU GMP standards. Photo: DHG Pharma

DHG Pharma has consistently earned consumer trust through awards such as Top 10 Prestigious Pharmaceutical Enterprises and High-Quality Vietnamese Goods. The company actively contributes to the community and healthcare for people across various regions through over 100 programs annually.

Regarding future direction, Ishii said DHG Pharma is accelerating its long-term "growth pivot" strategy, focusing on product restructuring and cost optimization across the entire pharmaceutical value chain.

DHG Pharma has recently increased investment in international-standard technology and production. The company plans to expand production capacity, complete EU GMP certification for new production lines, and apply digital transformation and automation to enhance productivity and quality control.

Perspective view of the DHG Pharma factory. Photo: DHG Pharma

Perspective view of the DHG Pharma factory. Photo: DHG Pharma

Simultaneously, DHG Pharma is promoting new product development and technology transfer for Taisho's renowned products to strengthen domestic competitiveness with a differentiated product portfolio. In 2024, the company received registration numbers for 23 new products and added 13 more to its production line.

The company is developing e-commerce channels, expanding exports to potential markets, and penetrating deeper into the ASEAN market. DHG Pharma is also pursuing a long-term ESG (Environmental, Social, and Governance) sustainable development strategy. The company has published its Sustainability Report according to GRI standards since 2020, anticipating the "green investment" trend in the pharmaceutical industry.

Van Ha